A first-in-human phase 1/1b study of receptor tyrosine kinase (RTK) inhibitor, MGCD516, in patients with advanced solid tumors

被引：0
|
作者：
Schwartz, G. [1 ]
Adkins, D. [2 ]
Heist, R. [3 ]
Werner, T. [4 ]
Abbott, M. [1 ]
Barber, S. [2 ]
Slusarz, K. [3 ]
Agarwal, N. [4 ]
Neuteboom, S. [5 ]
Faltaos, D. [5 ]
Chen, I. [5 ]
Christensen, J. [6 ]
Chao, R. [5 ]
Bauer, T. [7 ]
机构：
[1] Columbia Univ, Div Hematol & Oncol, Med Ctr, New York, NY USA
[2] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA
[3] Massachusetts Gen Hosp, Ctr Canc, Hematol Oncol, Boston, MA USA
[4] Huntsman Canc Inst, Div Oncol, Salt Lake City, UT USA
[5] Mirati Therapeut, Clin Sci, San Diego, CA USA
[6] Mirati Therapeut, Discovery & Translat Sci, San Diego, CA USA
[7] Tennessee Oncol PLLC, Oncol, Sarah Cannon Res Inst, Nashville, TN USA
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)30233-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
370
引用
收藏
页码：S78 / S78
页数：1
相关论文
共 50 条
  • [21] First-in-human phase 1/1b trial of the first-in-class bi-steric mTORC1-selective inhibitor RMC-5552 in patients with advanced solid tumors
    Schram, Alison M.
    Nagash, Abdul Rafeh
    Haura, Eric B.
    Riess, Jonathan W.
    Ulahannan, Susanna V.
    Ou, Sai-Hong I.
    Capasso, Anna
    Munster, Pamela N.
    Cheng, Michael L.
    Gustafson, W. Clay
    Bitman, Bojena
    Kar, Sumit
    Wang, Zhican
    Tao, Lin
    Meyerowitz, Justin G.
    Burns, Howard A.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [22] A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors
    Michael Carducci
    Montaser Shaheen
    Ben Markman
    Sara Hurvitz
    Daruka Mahadevan
    Dusan Kotasek
    Oscar B. Goodman
    Erik Rasmussen
    Vincent Chow
    Gloria Juan
    Gregory R. Friberg
    Erick Gamelin
    Florian D. Vogl
    Jayesh Desai
    Investigational New Drugs, 2018, 36 : 1060 - 1071
  • [23] A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors
    Carducci, Michael
    Shaheen, Montaser
    Markman, Ben
    Hurvitz, Sara
    Mahadevan, Daruka
    Kotasek, Dusan
    Goodman, Oscar B.
    Rasmussen, Erik
    Chow, Vincent
    Juan, Gloria
    Friberg, Gregory R.
    Gamelin, Erick
    Vogl, Florian D.
    Desai, Jayesh
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (06) : 1060 - 1071
  • [24] First-in-human phase 1 study of E7090, a novel selective inhibitor of FGFRs, in patients with advanced solid tumors
    Koyama, Takafumi
    Shimizu, Toshio
    Iwasa, Satoru
    Fujiwara, Yutaka
    Kondo, Shunsuke
    Kitano, Shigehisa
    Yonemori, Kan
    Shimomura, Akihiko
    Iizumi, Sakura
    Sasaki, Tatsuya
    Furuse, Junji
    Yamamoto, Noboru
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [25] A phase 1/1b first-in-human (FIH) study of JZP898 as monotherapy and in combination with pembrolizumab in adult patients with advanced or metastatic solid tumors.
    McKean, Meredith
    Hutson, Thomas E.
    Piha-Paul, Sarina A.
    Micaily, Ida
    Liao, Mingxiang
    Humphreys, Robin
    Brock, Graham
    Sahr, Natasha
    Amber, Vian
    Spira, Alexander I.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] First-in-human phase 1 study of DS-1062a in patients with advanced solid tumors.
    Sands, Jacob M.
    Shimizu, Toshio
    Garon, Edward B.
    Greenberg, Jonathan
    Guevara, Ferdinand M.
    Heist, Rebecca Suk
    Kobayashi, Fumiaki
    Noguchi, Yutaka
    Okajima, Daisuke
    Tajima, Naoyuki
    Spira, Alexander I.
    Yamamoto, Noboru
    Lisberg, Aaron Elliott
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] First-in-human phase 1 study of SPH4336, a novel cyclin-dependent kinase 4/6 inhibitor, in patients with advanced solid tumors
    Wang, Yong-Sheng
    Jiang, Yu
    Sun, Meili
    Liang, Xu
    Li, Huiping
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] Phase I first-in-human study of the polo-like kinase-1 selective inhibitor, GSK461364, in patients with advanced solid tumors
    Olmos, D.
    Allred, A.
    Sharma, R.
    Brunetto, A.
    Smith, D.
    Murray, S.
    Barker, D.
    Taegtmeyer, A.
    de Bono, J.
    Blagden, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] A phase I first-in-human study of the polo-like kinase 1-selective inhibitor, GSK461364, in patients with advanced solid tumors
    Blagden, S.
    Olmos, D.
    Sharma, R.
    Barriuso, J.
    Medani, H.
    Versola, M.
    Murray, S.
    Smith, D. A.
    Dar, M. M.
    deBono, J. S.
    EJC SUPPLEMENTS, 2008, 6 (12): : 135 - 136
  • [30] A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and-2 Inhibitor, in Patients with Advanced Solid Tumors
    Dowlati, Afshin
    Vlahovic, Gordana
    Natale, Ronald B.
    Rasmussen, Erik
    Singh, Indrajeet
    Hwang, Yuying C.
    Rossi, John
    Bass, Michael B.
    Friberg, Gregory
    Pickett, Cheryl A.
    CLINICAL CANCER RESEARCH, 2016, 22 (18) : 4574 - 4584
12345